Serabelisib (MLN1117) is a selectivep110αinhibitor with anIC₅₀of 15 nM.

Serabelisib (MLN1117) inhibits Akt phosphorylation and growth inPIK3CAmutant breast cancer cells with IC₅₀s around 2 μM, yet has no effect on cells lackingPTEN. BCR-stimulated B cells treated with 1 μM Serabelisib (MLN1117) displays a significant reduction (up to 50%) in the magnitude of the phosphorylated Akt (p-Akt) signal measured by intracellular flow cytometry. The effect of Serabelisib is dose-dependent^[1].

Treatment with Serabelisib (MLN1117) at 30 and 60 mg/kg causes little reduction of TNP-specific IgG3. Notably, reduction of TNP-specific IgG3 at higher doses of Serabelisib (MLN1117) (120 mg/kg) is observed, consistent with the partial reduction in cell division in B cells treated with Serabelisib before anti-IgM stimulation. However, 120 mg/kg is above the effective dose of Serabelisib (MLN1117) for tumor growth inhibition (30-60 mg/kg)^[1].

363.37

Solid

C₁₉H₁₇N₅O₃

1268454-23-4

Room temperature in continental US; may vary elsewhere.

DMSO : 6.4 mg/mL(17.61 mM;Need ultrasonic and warming)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。